Symbiotic relationship of pharmacogenetics and drugs of abuse

AAPS Journal

Volumn 8, Issue 1, 2006, Pages

  Rutter, Joni L ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Addiction; Pharmacogenomics; Psychiatric disease; SNP; Treatment

Indexed keywords

ALCOHOL; AMFEBUTAMONE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; CHOLINESTERASE; COCAINE; COTININE; CYTOCHROME P450; CYTOCHROME P450 2A6; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; METHAMPHETAMINE; METHYLPHENIDATE; MORPHINE; MU OPIATE RECEPTOR; NALTREXONE; NARCOTIC ANALGESIC AGENT; NICOTINE; NICOTINE GUM; NICOTINE PATCH; OPIATE DERIVATIVE; OPIATE RECEPTOR; PLACEBO; RIMONABANT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VARENICLINE;

ALCOHOLISM; BIOTECHNOLOGY; CIGARETTE SMOKING; CLINICAL TRIAL; DATA ANALYSIS; DIAGNOSTIC PROCEDURE; DRUG ABUSE; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HEROIN DEPENDENCE; HUMAN; HUMAN GENOME; LIVER TOXICITY; MEDICAL DECISION MAKING; NICOTINE REPLACEMENT THERAPY; NONHUMAN; OPIATE ADDICTION; PAIN; PHARMACOGENETICS; PHARMACOGENOMICS; PREDICTION; REVIEW; SEQUENCE ANALYSIS; TOBACCO DEPENDENCE; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

HUMANS; PHARMACOGENETICS; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; VARIATION (GENETICS);

EID: 33645472872     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj080121     Document Type: Review

References (105)

1. Uhl GR, Grow RW. The burden of complex genetics in brain disorders. Arch Gen Psychiatry. 2004;61:223-229.
2. Lichtermann D, Franke P, Maier W, Rao ML. Pharmacogenomics and addiction to opiates. Eur J Pharmacol. 2000;410:269-279.
3. Berrettini W, Bierut L, Crowley T, et al. Letter - Setting priorities for genomic research. Science. 2004;304:1445-1447.
4. Goldman D, Oroszi G, Ducci F. The genetics of addictions: Uncovering the genes. Nat Rev Genet. 2005;6:521-532.
5. Lessov CN, Swan GE, Ring HZ, Khroyan TV, Lerman C. Genetics and drug use as a complex phenotype. Subst Use Misuse. 2004;39:1515-1569.
6. Hall WD. Will nicotine genetics and a nicotine vaccine prevent cigarette smoking and smoking-related diseases? PLoS Med. 2005;2:e266.
7. Merikangas KR, Risch N. Setting priorities for genomic research. Science. 2003;302:599-601.
8. Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science. 1999;286:487-491.
9. Miksys S, Tyndale RF. Drug-metabolizing cytochrome P450s in the brain. J Psychiatry Neurosci. 2002;27:406-415.
10. Peto R. Smoking and death: The past 40 years and the next 40. BMJ. 1994;309:937-939.
11. Benowitz NL. Drug therapy: Pharmacologic aspects of cigarette smoking and nicotine addiction. N Engl J Med. 1988;319:1318-1330.
12. Bjartveit K, Tverdal A. Health consequences of smoking 1-4 cigarettes per day. Tob Control. 2005;14:315-320.
13. Kawachi I, Colditz GA, Stampfer MJ, et al. Smoking cessation and time course of decreased risks of coronary heart disease in middle-aged women. Arch Intern Med. 1994; 154:169-175.
14. Rosengren A, Wilhelmsen L, Wedel H. Coronary heart disease, cancer and mortality in middle-aged light smokers. J Intern Med. 1992;231:357-362.
15. Prescott E, Scharling H, Osler M, et al. Importance of light smoking and inhalation habits on risk of myocardial infarction and all cause mortality: A 22-year follow-up of 12,149 men and women in the Copenhagen City heart study. J Epidemiol Community Health. 2002;56:702-706.
16. Shiffman S, Fischer LB, Zettler-Segal M, Benowitz NL. Nicotine exposure among nondependent smokers. Arch Gen Psychiatry. 1990;47:333-336.
17. Ellickson PL, McCaffrey DF, Ghosh-Dastidar B, Longshore DL. New inroads in preventing adolescent drug use: Results from a largescale trial of project ALERT in middle schools. Am J Public Health. 2003;93:1830-1836.
18. Hall W, Madden P, Lynskey M. The genetics of tobacco use: Methods, findings and policy implications. Tob Control. 2002;11:119-124.
19. Tyndale RF. Genetics of alcohol and tobacco use in humans. Ann Med. 2003;35:94-121.
20. Li MD, Cheng R, Ma JZ, Swan GE. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction. 2003;98:23-31.
21. Bierut LJ, Rice JP, Edenberg HJ, et al. Family-based study of the association of the dopamine D2 receptor gene (DRD2) with habitual smoking. Am J Med Genet. 2000;90:299-302.
22. Comings DE, Ferry L, Bradshaw-Robinson S, Burchette R, Chiu C, Muhleman D. The dopamine D2 receptor (DRD2) gene: A genetic risk factor in smoking. Pharmacogenetics. 1996;6:73-79.
23. B receptor subunit 2 (GABAB2) gene are significantly associated with nicotine dependence. Am J Hum Genet. 2005;76:859-864.
24. Vandenbergh DJ, Kozlowski LT, Bennett CJ, et al. DAT's not all, but it may be more than we realize. Nicotine Tob Res. 2002;4:251-252.
25. Lerman C, Shields PG, Audrain J, et al. The role of the serotonin transporter gene in cigarette smoking. Cancer Epidemiol Biomarkers Prev. 1998;7:253-255.
26. Shields PG, Lerman C, Audrain J, et al. Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians. Cancer Epidemiol Biomarkers Prev. 1998;7:453-458.
27. Sabol SZ, Nelson ML, Fisher C, et al. A genetic association for cigarette smoking behavior. Health Psychol. 1999;18:7-13.
28. Sullivan PF, Jiang Y, Neale MC, Kendler KS, Straub RE. Association of the tryptophan hydroxylase gene with smoking initiation but not progression in nicotine dependence. Am J Med Genet. 2001;105:479-484.
29. Swan GE, Valdes AM, Ring HZ, et al. Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J. 2005;5:21-29.
30. McKinney EF, Walton RT, Yudkin P, et al. Association between polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers. Pharmacogenetics. 2000;10:483-491.
31. Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKKI: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat. 2004;23:540-545.
32. Kreek MJ, Bart G, Lilly C, Laforge KS, Nielsen DA. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev. 2005;57:1-26.
33. Xie W, Altamirano CV, Bartels CF, Speirs RJ, Cashman JR, Lockridge O. An improved cocaine hydrolase: The A328Y mutant of human butyrylcholinesterase is 4-fold more efficient. Mol Pharmacol. 1999;55:83-91.
34. Mogil JS, Miertmeister F, Seifert F, et al. Variable sensitivity to noxious heat is mediated by differential expression of the CGRP gene. Proc Natl Acad Sci USA. 2005;102:12938-12943.
35. Owens JC, Balogh SA, McClure-Begley TD, et al. Alpha 4 beta 2* nicotine acetylcholine receptors modulate the effects of ethanol and nicotine on the acoustic startle response. Alcohol Clin Exp Res. 2003;27:1867-1875.
36. Cohen C, Kodas E, Griebel G. CBI receptor antagonists for the treatment of nicotine addiction. Pharmacol Biochem Behav. 2005;81:387-395.
37. Castane A, Berrendero F, Maldonado R. The role of the cannabinoid system in nicotine addiction. Pharmacol Biochem Behav. 2005;81:381-386.
38. Zubieta JK, Heitzeg MM, Smith YR, et al. COMT vall 58met genotype affects mu-opioid neurotransmitter responses to a pain stressor Science. 2003;299:1240-1243.
39. Li T, Chen CK, Hu X, et al. Association analysis of the DRD4 and COMT genes in methamphetamine abuse. Am J Med Genet B Neuropsychiatr Genet. 2004;129:120-124.
40. Vandenbergh DJ, Rodriguez LA, Hivert E, et al. Long forms of the dopamine receptor (DRD4) gene VNTR are more prevalent in substance abusers: No interaction with functional alleles of the catechol-o-methyltransferase (COMT) gene. Am J Med Genet. 2000;96:678-683.
41. Tyndale RF, Sellers EM. Variable CYP2A6-mediated. nicotine metabolism alters smoking behavior and risk. Drug Metab Dispos. 2001;29:548-552.
42. Pianezza ML, Sellers EM, Tyndale RF. Nicotine metabolism defect reduces smoking. Nature. 1998;393:750.
43. Gelernter J, Kranzler HR, Satel SL, Rao PA. Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. Neuropsychopharmacology. 1994;11:195-200.
44. Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J. 2001;1:152-156.
45. Lott DC Jr, Kim S-J Jr, Cook EH Jr, de Wit H. Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology. 2005;30:602-609.
46. Stein MA, Waldman ID, Sarampote CS, et al. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology. 2005;30:1374-1382.
47. Chen R, Han DD, Gu HH. A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate. J Neurochem. 2005;94:352-359.
48. Lerman C, Jepson C, Wileyto EP, et al. Role of Functional Genetic Variation in the Dopamine D2 Receptor (DRD2), in Response to Bupropion and Nicotine Replacement Therapy for Tobacco Dependence: Results of Two Randomized Clinical Trials. Neuropsychopharmacology. 2006;31:231-242.
49. Xu K, Lichtermann D, Lipsky RH, et al. Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroin dependence in 2 distinct populations. Arch Gen Psychiatry. 2004;61:597-606.
50. Noble EP, Zhang X, Ritchie TL, Sparkes RS. Haplotypes at the DRD2 locus and severe alcoholism. Am J Med Genet. 2000;96:622-631.
51. Gelernter J, Kranzler H. D2 dopamine receptor gene (DRD2) allele and haplotype frequencies in alcohol dependent and control subjects: No association with phenotype or severity of phenotype. Neuropsychopharmacology. 1999;20:640-649.
52. Sander T, Ladehoff M, Samochowiec J, Finckh U, Rommelspacher H, Schmidt LG. Lack of an allelic association between polymorphisms of the dopamine D2 receptor gene and alcohol dependence in the German population. Alcohol Clin Exp Res. 1999;23:578-581.
53. Gelernter J, Kranzler H, Satel SL. No association between D2 dopamine receptor (DRD2) alleles or haplotypes and cocaine dependence or severity of cocaine dependence in European- and African-Americans. Biol Psychiatry. 1999;45:340-345.
54. Goldman D, Urbarnek M, Guenther D, Robin R, Long JC. Linkage and association of a functional DRD2 variant [Ser311 Cys] and DRD2 markers to alcoholism, substance abuse and schizophrenia in Southwestern American Indians. Am J Med Genet. 1997;74:386-394.
55. Chen CK, Hu X, Lin SK, et al. Association analysis of dopamine D2-like receptor genes and methamphetamine abuse. Psychiatr Genet. 2004;14:223-226.
56. Chang FM, Ko HC Lu RB, Pakstis AJ, Kidd KK. The dopamine D4 receptor gene (DRD4) is not associated with alcoholism in three Taiwanese populations: Six polymorphisms tested separately and as haplotypes. Biol Psychiatry. 1997;41:394-405.
57. Nishiyama T, Ikeda M, Iwata N, et al. Haplotype association between GABAA receptor gamma2 subunit gene (GABRG2) and methamphetamine use disorder. Pharmacogenomics J. 2005;5:89-95.
58. Hashimoto T, Hashimoto K, Matsuzawa D, et al. A functional glutathione S-transferase P1 gene polymorphism is associated with methamphetamine-induced psychosis in Japanese population. AM J Med Genet B Neuropsychiatr Genet. 2005; 135:5-9.
59. Zimniak P, Nanduri B, Pikula S, et al. Naturally occurring human glutathione S-transferase GSTPI -1 isoforms with isoleucine and valine in position 104 differ in enzymic properties. Eur J Biochem. 1994;224:893-899.
60. Szumlinski KK, Abernathy KE, Oleson EB, et al. Homer isoforms differentially regulate cocaine-induced neuroplasticity. Neuropsychopharmacology. 2005; 14.Epub ahead of print.
61. Mogil JS, Ritchie J, Smith SB, et al. Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans. J Med Genet. 2005;42:583-587.
62. Mogil JS, Wilson SG, Chesler EJ, et al. The melanocortin- 1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc Natl Acad Sci USA. 2003;100:4867-4872.
63. Kim H, Neubert JK, San MA, et al. Genetic influences on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain. 2004;109:488-496.
64. Lerman C, Wileyto EP, Patterson F, et al. The flinctional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J. 2004;4:184-192.
65. Gelernter J, Kranzler H, Cubells J. Genetics of two μ opioid receptor gene (OPRM1) exon 1 polymorphisms: Population studies, and allele frequencies in alcohol- and drug-dependent subjects. Mol Psychiatry. 1999;4:476-483.
66. Bart G, Heilig M, LaForge KS, et al. Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol Psychiatry. 2004;9:547-549.
67. Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters betaendorphin binding and activity: Possible implications for opiate addiction. Proc Natl Acad Sci USA. 1998;95:9608-9613.
68. Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem. 2001;276:3130-3137.
69. Beyer A, Kock T, Schroder H, Schulz S, Hollt V Effect of the Al18G polymorphism on binding affinity, potency and agonistmediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem. 2004;89:553-560.
70. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem. 2005;280:32618-32624.
71. Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the μ-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003;28:1546-1552.
72. Lotsch J, Skarke C, Grosch S, Darimont J, Schmidt H, Geisslinger G. The polymorphism Al18G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics. 2002;123-9.
73. Fillingim RB, Kaplan L, Stand R, et al. The Al18G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J Pain. 2005;6:159-167.
74. Fiore MC. Treating tobacco use and dependence: An introduction to the US Public Health Service Clinical Practice Guideline. Respir Care. 2000;45:1196-1199.
75. National Institute on Drug Abuse. Research Report Series: Nicotine Addiction. NIH Publ No 01-4342. 2001. Bethesda, TYM: NIDA. Available at: http://www.nida.nih.gov/researchreports/~icotine/nicotine.html. Accessed February 23, 2006.
76. Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation: A meta-analysis. JAMA. 1994;271:1940-1947.
77. Paoletti P, Fornai E, Maggiorelli F, et al. Importance of baseline cotinine plasma values in smoking cessation: Results from a double-blind study with nicotine patch. Eur Respir J. 1996;9:643-651.
78. Pickworth WB, Fant RV, Butschky MF, Henningfield JE. Effects of transdermal nicotine delivery on measures of acute nicotine withdrawal. J Pharmacol Exp Ther. 1996;279:450-456.
79. Foulds J, Burke M, Steinberg M, Williams JM, Ziedonis DM. Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs. 2004;9:39-53.
80. Anthenelli RM, Rimonabant helps for smoking cessation, weight loss. ACC 53rd Annual Scientific Session: Late-Breaking Clinical Trials; March 9, 2004; New Orleans, LA.
81. Heading CE. NicVAX Nabi Biopharmaceuticals. IDrugs. 2003;6:1178-1181.
82. Cemy T. Anti-nicotine vaccination: Where are we now? Recent Results Cancer Res. 2005;166:167-175.
83. Hatsukami DK, Rennard S, Jorenby D, et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther. 2005;78:456-467.
84. Dale LC, Glover ED, Sachs DP, et al. Bupropion for smoking cessation: Predictors of successfid outcome. Chest. 2001;119:1357-1364.
85. Merikangas KR, Stolar M, Stevens DE, et al. Familial transmission of substance use disorders. Arch Gen Psychiatry. 1998;55:973-979.
86. Tsuang MT, Lyons MJ, Meyer JM, et al. Co-occurrence of abuse of different drugs in men: The role of drug-specific and shared vulnerabilities. Arch Gen Psychiatry. 1998;55:967-972.
87. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiology Catchment Area (ECA) study. JAMA. 1990;264:2511-2518.
88. Ikeda K, Soichiro I, Han W, Hayashida M, Uhl GR, Sora I. How individual sensitivity to opiates can be predicted by gene analyses. Trends Pharmacol Sci. 2005;26:311-317.
89. Ross JR, Rutter D, Welsh K, et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J. 2005;5:324-336.
90. Tiseo PJ, Thaler HT, Lapin J, Inturrisi CE, Portenoy RK, Foley KM. Morphine-6-glucuronide concentrations and opioid-related side effects: a Survey in cancer patients. Pain. 1995;61:47-54.
91. MacGregor AJ, Griffiths GO, Baker J, Spector TD. Determinants of pressure pain threshold in adult twins: Evidence that shared environmental influences predominate. Pain. 1997;73:253-257.
92. Rainville P, Duncan GH, Price DD, Carrier B, Bushnell MC. Pain affect encoded in human anterior cingulate but not somatosensory cortex. Science. 1997;277:968-971.
93. Snyder SH. Amphetamine psychosis: A "model" schizophrenia mediated by catecholamines. Am J Psychiatry. 1973;130:61-67.
94. Sato M, Chen CC, Akiyama K, Otsuki S. Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry. 1983;18:429-440.
95. Volkow ND. Message from the Director on Amphetamine Abuse. Available at: http://www.nida.nih.gov/about/welcome/Messagemeth405.html. Accessed February 23, 2006.
96. Kendler KS, Karkowski LM, Neale MC, Prescott CA. Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins. Arch Gen Psychiatry. 2000;57:261-269.
97. Tsuang MT, Lyons MJ, Eisen SA, et al. Genetic influences on DSMIII-R drug abuse and dependence: A study of 3,372 twin pairs. Am J Med Genet. 1996;67:473-477.
98. Leshner AI. Addiction is a brain disease, and it matters. Science. 1997;278:45-47.
99. Merikangas KR, Risch N. Will the genomics revolution revolutionize psychiatry? Am J Psychiatry. 2003; 160:625-635.
100. Croghan TW, Tomlin M, Pescosolido BA, et al. American attitudes toward and willingness to use psychiatric medications. J Nerv Ment Dis. 2003;191:166-174.
101. Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: A meta-analysis. JAMA. 2004;291:1887-1896.
102. Kendler KS, Jacobson KC, Prescott CA, Neale MC. Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. Am J Psychiatry. 2003;160:687-695.
103. Bierut W, Rice JP, Goate A, et al. A genomic scan for habitual smoking in families of alcoholics: Common and specific genetic factors in substance dependence. Am J Med Genet A. 2004;124:19-27.
104. Frueh FW, Goodsaid F, Rudman A, Huang S-M, Lesko LJ. The need for education in pharmacogenomics: A regulatory perspective. Pharmacogenomics J. 2005;5:218-220.
105. Rubin DL, Thorn C, Klein TE, Altman RB. A statistical approach to scanning the biomedical literature for pharmacogenetics knowledge. J Am Med Inform Assoc. 2005;12:121-129.